

The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for the Study of the Liver

Spontaneous Resolution of Multiple Hepatic Masses: Hepatic Inflammatory Pseuduotumor

Xingshun Qi,* Lei Han,** Ankur Arora,*** Yue Hou,* Ran Wang,* Sha Chang,* Xiaozhong Guo*

* Department of Gastroenterology, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang, China. ** Department of Hepatobiliary Surgery, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang, China. *** Department of Radiology, Worthing Hospital, Western Sussex NHS Foundation Trust, West Sussex, UK.

CASE PRESENTATION

A previously healthy 59-year-old female presented with intermittent fever for 4 days. The highest temperature was 40°C. Buluofen was given at home, but fever relapsed. She denied any history of liver diseases. She did not smoke or have any history of alcohol or drug abuse. On physical examinations, there were no positive signs. At our admission, abnormal laboratory tests (2016-12-19) were primarily shown as follows: white blood cell was 12.3 x $10^{9}/L$ (reference range: 3.5-9.5 x $10^{9}/L$), percentage of neutrophil was 81.9% (reference range: 40-75%), C reactive protein was 99.4 mg/L (reference range: 0-8 mg/L), procalcitonin was 0.378 ng/mL (reference range: 0-0.05 ng/mL), total bilirubin was 48.88 umol/L (reference range: 5.1-22.2 umol/L), direct bilirubin was 17.2 umol/L (reference range: 0-8.6 umol/L), aspartate aminotransferase was 111.68 U/L (reference range: 13-35 U/L), alanine aminotransferase was 181.88 (reference range: 7-40 U/L), alkaline phosphatase was 154.83 U/L (reference range: 35-135 U/L), gamma-glutamyl transferase was 164.91 U/L (reference range: 7-45 U/L), albumin was 38.2 g/L (reference range: 40-55 g/L), mycoplasma pneumoniae antibody IgM was weakly positive, and anti-influenza virus antibody IgM was weakly positive. Viral hepatitis A, B, C, and E were excluded. Alfa-fetal protein, carcinoembryonic antigen, CA50, CA125, CA153, CA199, and CA242 levels were within the normal range. HIV was negative. Creatinine and prothrombin time were within the normal range. Antinuclear antibody, anti mitochondrial antibody, anti mitochondrial antibody type M2, and anti smooth muscle antibody were negative. IgG4 test was not available. Intravenous infusion of antibiotics and hepato-protective drugs was given. Six days after treatment, the symptoms gradually disappeared. Thus, blood culture was not performed. Laboratory tests (2016-12-25) were primarily shown as follows: white blood cell was 9.5 x 10⁹/L, percentage of neutrophil was 68.1%, total bilirubin was 11.4 umol/L, direct bilirubin was 5.3 umol/L, aspartate aminotransferase was 13.3 U/L, alanine aminotransferase was 51.01 U/L, alkaline phosphatase was 217.21 U/L, and gamma-glutamyl transferase was 175.26 U/L. Notably, computed tomography (CT) scans showed multiple low density lesions on the liver, some of them exhibiting a "bulls eye" sign (Figure 1). Hepatic metastatic malignancy was suspected. A positron emission tomography-computed tomography (PET-CT) scan was further performed, which showed that the lesions were highly metabolic. Hepatic epithelioid hemangioendothelioma was suspected. Finally, a targeted liver biopsy under ultrasound guidance was performed, which excluded malignancy. Because the diagnosis was unclear, no active anti-tumor treatment or surgery was planned. Follow-up magnetic resonance imaging (MRI) surprisingly revealed no hepatic masses (Figure 1). About one month later, another MRI was performed, which confirmed a normal liver again (Figure 1). Based on the history, clinical presentations, and imaging findings, a diagnosis of hepatic inflammatory pseuduotumor was considered. Now, she is keeping well without any other complaints. Laboratory tests (2017-2-25) were primarily shown as follows: white blood cell was 5.5 x 10⁹/L, percentage of neutrophil was 43.4%, total bilirubin was 10.5 umol/L, direct bilirubin was 3.3 umol/L, aspartate aminotransferase was 32.57 U/L, alanine aminotransferase was 38.54 U/L, alkaline phosphatase was 95.96 U/L, and gamma-glutamyl transferase was 51.39 U/L.

Manuscript accepted: March 10, 2017.

DOI:10 5604/16652681 1235490

Manuscript received: March 10, 2017.

^{© 2019,} Fundación Clínica Médica Sur, A.C. Published by Elsevier España S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).



Figure 1. Contrast enhanced CT and MRI images of the liver.

DISCUSSION

Hepatic inflammatory pseuduotumor is a rare disease, including inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and plasma cell granuloma. Inflammatory pseudotumor of the liver was firstly described by Pack,¹ which was characterized by dominant spindle cell proliferation with varying inflammatory components.^{2,3} The etiology of hepatic inflammatory pseuduotumor remains unclear.^{3,4} It may be caused by infection, autoimmune conditions, trauma, and surgical inflammation.^{5,6} Abdominal pain is the most common symptom.⁷ Other symptoms include fever and malaise. Some cases are asymptomatic. Hepatic inflammatory pseuduotumor is more frequently seen in Asia and is more common in men.³ Imaging findings are often non-specific and are sometime misinterpreted as malignancy. Liver biopsy can be helpful in clinching the diagnosis. Surgery may be preferable, especially in patients with low surgical risk.³ Only a small proportion of patients suffer from the recurrence or metastasis after partial hepatectomy.^{8,9} Observation or conservative therapy is an alternative.

In conclusion, we report a female patient with multiple hepatic inflammatory pseuduotumors which resolved spontaneously. Because definitive diagnostic criteria remain unavailable, our case underwent CT, PET-CT, MRI, and liver biopsy to exclude malignancy. A close follow-up observation remains crucial. Lastly, a wait-and-see strategy may be appropriate if a hepatic inflammatory pseudotumor liver is diagnosed.

CONFLICT OF INTEREST

None.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Xingshun Qi, Yue Hou, Sha Chang, Xiaozhong Guo: treated, cared, and followed the case.

Xingshun Qi, Lei Han, Ankur Arora: discussed the case and interpreted the images.

Xingshun Qi, Ran Wang: reviewed the literature and drafted the manuscript.

All authors have made an intellectual contribution to the manuscript and approved the submission.

REFERENCES

1. Pack GT, Baker HW. Total right hepatic lobectomy; report of a case. *Ann Surg* 1953; 138: 253-8.

- Wu CH, Chiu NC, Yeh YC, Kuo Y, Yu SS, Weng CY, Liu CA, et al. Uncommon liver tumors: Case report and literature review. *Medicine (Baltimore)* 2016; 95: e4952.
- Tang L, Lai EC, Cong WM, Li AJ, Fu SY, Pan ZY, Zhou WP, et al. Inflammatory myofibroblastic tumor of the liver: a cohort study. *World J Surg* 2010; 34: 309-13.
- Balabaud C, Bioulac-Sage P, Goodman ZD, Makhlouf HR. Inflammatory pseudotumor of the liver: a rare but distinct tumor-like lesion. *Gastroenterol Hepatol (NY)* 2012; 8: p. 633-4.
- 5. Narla LD, Newman B, Spottswood SS, Narla S, Kolli R. Inflammatory pseudotumor. *Radiographics* 2003; 23(3): 719-29.
- Sanders BM, West KW, Gingalewski C, Engum S, Davis M, Grosfeld JL. Inflammatory pseudotumor of the alimentary tract: clinical and surgical experience. *J Pediatr Surg* 2001; 36: 169-73.
- 7. Aguirre-Garcia J. Inflammatory pseudotumor of the liver. *Ann Hepatol* 2004; 3:34.

- Zavaglia C, Barberis M, Gelosa F, Cimino G, Minola E, Mondazzi L, Bottelli R, et al. Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. *Ital J Gastroenterol* 1996; 28: 152-9.
- Pecorella I, Ciardi A, Memeo L, Trombetta G, de Quarto A, de Simone P, di Tondo U. Inflammatory pseudotumour of the liver-evidence for malignant transformation. *Pathol Res Pract* 1999; 195: 115-20.

Correspondence and reprint request: Xingshun Qi, MD. Department of Gastroenterology, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang, 110840 China. Tel.: 86-24-28897603. Fax: 86-24-28851113 E-mail: xingshunqi@126.com